Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
Nanobiotix, a late-stage clinical biotechnology firm, has requested a temporary trading halt of its ordinary shares on Euronext Paris to facilitate confirmation of investor allocations and pricing for its global equity offering. The offering includes a public sale of American Depositary Shares in the U.S. and shares plus pre-funded warrants in Euro…